We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




AI Tool Helps Make Real-Time Diagnosis During Surgery

By LabMedica International staff writers
Posted on 26 Dec 2022
Print article
Image: Deep-learning model improves image quality of frozen tissue samples to increase accuracy of time-critical pathology diagnostics (Photo courtesy of Pexels)
Image: Deep-learning model improves image quality of frozen tissue samples to increase accuracy of time-critical pathology diagnostics (Photo courtesy of Pexels)

When a patient undergoes a surgical operation to remove a tumor or treat a disease, the course of surgery is often not predetermined. To decide how much tissue needs to be removed, surgeons must know more about the condition they are treating, including a tumor’s margins, its stage and whether a lesion is malignant or benign - determinations that often hinge upon collecting, analyzing, and diagnosing a disease while the patient is on the operating table. When surgeons send samples to a pathologist for examination, both speed and accuracy are of the essence. The current gold-standard approach for examining tissues often takes too long and a faster approach, which involves freezing tissue, can introduce artifacts that can complicate diagnostics. Now, researchers have developed a new method that leverages artificial intelligence to translate between frozen sections and the gold-standard approach, thereby improving the quality of images to increase the accuracy of rapid diagnostics.

For making final diagnoses, pathologists use formalin-fixed and paraffin-embedded (FFPE) tissue samples - this method preserves tissue in a way that produces high-quality images but the process is laborious and typically takes 12 to 48 hours. For a rapid diagnosis, pathologists use an approach known as cryosectioning that involves fast freezing tissue, cutting sections, and observing these thin slices under a microscope. Cryosectioning takes minutes rather than hours but can distort cellular details and compromise or tear delicate tissue. Researchers at the Brigham and Women’s Hospital (Boston, MA, USA) have developed a deep-learning model that can be used to translate between frozen sections and more commonly used FFPE tissue. The team demonstrated that the method could be used to subtype different kinds of cancer, including glioma and non-small-cell lung cancer.

The researchers validated their findings by recruiting pathologists to a reader study in which they were asked to make a diagnosis from images that had gone through the AI method and traditional cryosectioning images. The AI method not only improved image quality but also improved diagnostic accuracy among experts. The algorithm was also tested on independently collected data from Turkey. The researchers note that in the future, prospective clinical studies should be conducted to validate the AI method and determine if it can contribute to diagnostic accuracy and surgical decision-making in real hospital settings.

“We are using the power of artificial intelligence to address an age-old problem at the intersection of surgery and pathology,” said corresponding author Faisal Mahmood, PhD, of the Division of Computational Pathology at BWH. “Making a rapid diagnosis from frozen tissue samples is challenging and requires specialized training, but this kind of diagnosis is a critical step in caring for patients during surgery.”

“Our work shows that AI has the potential to make a time-sensitive, critical diagnosis easier and more accessible to pathologists,” said Mahmood. “And it could potentially be applied to any type of cancer surgery. It opens up many possibilities for improving diagnosis and patient care.”

Related Links:
Brigham and Women’s Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.